Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Daniel Rayson; Sasha Lupichuk; Kylea Potvin; Susan Dent; Tamara Shenkier; Sukhbinder Dhesy-Thind; Susan L. Ellard; Catherine Prady; Muhammad Salim; Patricia Farmer; Ghasson Allo; Ming Sound Tsao; Alison Allan; Olga Ludkovski; Maria Bonomi; Dongsheng Tu; Linda Hagerman; Rachel Goodwin; Elizabeth Eisenhauer; Penelope Bradbury

doi:10.1007/s10549-016-3812-1

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Daniel Rayson, Sasha Lupichuk, Kylea Potvin, Susan Dent, Tamara Shenkier, Sukhbinder Dhesy-Thind, Susan L. Ellard, Catherine Prady, Muhammad Salim, Patricia Farmer, Ghasson Allo, Ming Sound Tsao, Alison Allan, Olga Ludkovski, Maria Bonomi, Dongsheng Tu, Linda Hagerman, Rachel Goodwin, Elizabeth Eisenhauer, Penelope Bradbury

科研成果: 期刊稿件 › 文章 › 同行评审

40 引用（Scopus）

源语言	英语
页（从-至）	109-116
页数	8
期刊	Breast Cancer Research and Treatment
卷	157
期	1
DOI	https://doi.org/10.1007/s10549-016-3812-1
出版状态	已出版 - 5月 1 2016
已对外发布	是

!!!ASJC Scopus Subject Areas

肿瘤学
癌症研究

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1007/s10549-016-3812-1

其它文件与链接

指纹

探究 'Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer' 的科研主题。它们共同构成独一无二的指纹。

引用此

Rayson, D., Lupichuk, S., Potvin, K., Dent, S., Shenkier, T., Dhesy-Thind, S., Ellard, S. L., Prady, C., Salim, M., Farmer, P., Allo, G., Tsao, M. S., Allan, A., Ludkovski, O., Bonomi, M., Tu, D., Hagerman, L., Goodwin, R., Eisenhauer, E., & Bradbury, P. (2016). Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Research and Treatment, 157(1), 109-116. https://doi.org/10.1007/s10549-016-3812-1

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. / Rayson, Daniel; Lupichuk, Sasha; Potvin, Kylea 等.
在: Breast Cancer Research and Treatment, 卷 157, 号码 1, 01.05.2016, 页码 109-116.

科研成果: 期刊稿件 › 文章 › 同行评审

Rayson, D, Lupichuk, S, Potvin, K, Dent, S, Shenkier, T, Dhesy-Thind, S, Ellard, SL, Prady, C, Salim, M, Farmer, P, Allo, G, Tsao, MS, Allan, A, Ludkovski, O, Bonomi, M, Tu, D, Hagerman, L, Goodwin, R, Eisenhauer, E & Bradbury, P 2016, 'Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer', Breast Cancer Research and Treatment, 卷 157, 号码 1, 页码 109-116. https://doi.org/10.1007/s10549-016-3812-1

Rayson D, Lupichuk S, Potvin K, Dent S, Shenkier T, Dhesy-Thind S 等. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Research and Treatment. 2016 5月 1;157(1):109-116. doi: 10.1007/s10549-016-3812-1

@article{a962268e0e184a6cbbd6d168fcd42b9b,

title = "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer",

keywords = "Clinical activity, Foretinib, MET targeting, Triple-negative breast cancer",

author = "Daniel Rayson and Sasha Lupichuk and Kylea Potvin and Susan Dent and Tamara Shenkier and Sukhbinder Dhesy-Thind and Ellard, {Susan L.} and Catherine Prady and Muhammad Salim and Patricia Farmer and Ghasson Allo and Tsao, {Ming Sound} and Alison Allan and Olga Ludkovski and Maria Bonomi and Dongsheng Tu and Linda Hagerman and Rachel Goodwin and Elizabeth Eisenhauer and Penelope Bradbury",

note = "Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York.",

year = "2016",

month = may,

day = "1",

doi = "10.1007/s10549-016-3812-1",

language = "English",

volume = "157",

pages = "109--116",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - Canadian Cancer Trials Group IND197

T2 - a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

AU - Rayson, Daniel

AU - Lupichuk, Sasha

AU - Potvin, Kylea

AU - Dent, Susan

AU - Shenkier, Tamara

AU - Dhesy-Thind, Sukhbinder

AU - Ellard, Susan L.

AU - Prady, Catherine

AU - Salim, Muhammad

AU - Farmer, Patricia

AU - Allo, Ghasson

AU - Tsao, Ming Sound

AU - Allan, Alison

AU - Ludkovski, Olga

AU - Bonomi, Maria

AU - Tu, Dongsheng

AU - Hagerman, Linda

AU - Goodwin, Rachel

AU - Eisenhauer, Elizabeth

AU - Bradbury, Penelope

PY - 2016/5/1

Y1 - 2016/5/1

KW - Clinical activity

KW - Foretinib

KW - MET targeting

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84969864747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969864747&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3812-1

DO - 10.1007/s10549-016-3812-1

M3 - Article

C2 - 27116183

AN - SCOPUS:84969864747

SN - 0167-6806

VL - 157

SP - 109

EP - 116

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -